Biotech company VALANX Biotech has raised €3 million to advance its lead antibody-drug conjugate (ADC) programme to treat metastatic triple-negative breast cancer. The company will use the financing for the pre-clinical development of VLX-ADC-001, a LIV-1-targeting ADC for metastatic triple-negative breast cancer (mTNBC), with candidate selection planned for June 2026. ADCs are a transformative class of therapies that […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!